Why emodepside formulation matters in resistant hookworm care
A new American Journal of Veterinary Research study is sharpening the message around emodepside use in dogs: formulation matters, and products that contain the same active ingredient can’t be assumed to behave the same way. In the crossover pharmacokinetic study, researchers compared three approaches in seven healthy client-owned dogs: oral administration of the FDA-approved feline topical emodepside/praziquantel solution, oral administration of the European canine modified-release emodepside tablet, and topical administration of the feline solution. The feline topical product, when given orally, produced markedly higher emodepside absorption than the canine tablet and failed bioequivalence testing, while topical administration produced plasma concentrations 36- to 122-fold lower than oral dosing. The authors concluded that the feline topical solution administered orally is not bioequivalent to the canine tablet and that topical use appears unsuitable for treating multi-anthelmintic drug-resistant hookworm infections in dogs. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals managing suspected resistant Ancylostoma caninum, this is a practical warning against dose-by-ingredient substitution. Emodepside has emerged as a last-line option in some resistant hookworm cases in the U.S., but it is not registered for dogs in the United States, and expert guidance has already urged careful case selection, heartworm screening, and close monitoring when oral extra-label use is considered. The new data suggest that switching between formulations could change exposure in clinically meaningful ways, with potential safety concerns if a feline topical product is given orally and potential lack of efficacy if it is used topically in dogs. (pubmed.ncbi.nlm.nih.gov)
What to watch: Expect this study to further influence resistant hookworm protocols, especially around extra-label emodepside use, formulation choice, and calls for a U.S.-approved canine option. (pubmed.ncbi.nlm.nih.gov)